Intensive Cholesterol Treatment Reduces Heart Attack Risk by a Third

New research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) indicates that more aggressive targets for low-density lipoprotein cholesterol (LDL-C) and earlier intensive treatment can significantly reduce the risk of major cardiovascular events.

Two separate studies presented at the session demonstrate the benefits of lowering cholesterol levels more intensively than previous conventional standards, both for patients with existing heart disease and those at high risk without diagnosed artery disease.

The Ez-PAVE Trial and Aggressive LDL-C Targets

The Ez-PAVE trial, the first randomized, head-to-head comparison of specific LDL-C targets in patients with atherosclerotic cardiovascular disease (ASCVD), found that targeting an LDL-C level of less than 55 mg/dL reduced the rate of major cardiovascular events by one-third.

This more aggressive target was compared against the conventional target of less than 70 mg/dL. The results, presented on March 28, 2026, showed a significantly lower three-year risk of major cardiovascular events without compromising patient safety.

Byeong-Keuk Kim, MD, lead author of the study and director of the Cardiac Catheterization and Intervention Department at Severance Hospital, Yonsei University College of Medicine, stated that the trial provides practical and clinically meaningful evidence for guiding the treatment of high-risk heart disease patients.

While medical guidelines had already begun recommending a shift from 70 mg/dL to 55 mg/dL for ASCVD patients, the Ez-PAVE trial helps fill a previous gap in the evidence supporting that recommendation.

Preventing First-Time Events in High-Risk Diabetes Patients

In a separate finding presented on March 30, 2026, researchers from Mass General Brigham reported that the cholesterol-lowering drug evolocumab can reduce the risk of first-time heart attacks and strokes by 31% in high-risk patients with diabetes.

This specific study focused on patients who were considered high risk but did not yet have diagnosed atherosclerosis, which is the build-up of plaque inside the artery walls.

Nicholas A. Marston, MD, MPH, a cardiologist with the Mass General Brigham Heart and Vascular Institute and the study’s corresponding author, noted that intensive cholesterol lowering has typically been reserved for patients who already have cardiovascular disease.

These results demonstrate the benefit of intensive lowering cholesterol earlier and should change how we think about the prevention of heart attacks, strokes and heart disease in patients without known significant atherosclerosis.

Nicholas A. Marston, MD, MPH

Medical Context of LDL Cholesterol and ASCVD

Atherosclerotic cardiovascular disease (ASCVD) occurs when plaque accumulates in the walls of the arteries. LDL-C is a primary contributor to this plaque buildup.

While cholesterol is necessary for cell membrane stability and the synthesis of hormones, excessive levels can lead to reduced blood perfusion.

This accumulation increases the risk of plaque rupture, a process that can trigger sudden and serious cardiac events, including strokes and heart attacks.

Therapies designed to reduce LDL-C levels aim to slow the buildup of this plaque in the artery walls, thereby reducing the likelihood of rupture and subsequent cardiovascular events.